The DOI matches its Crossref record.
Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis
Open accessAbstract
Recombinant adenoviruses are being developed for gene therapy of inherited disorders such as cystic fibrosis because they efficiently transduce recombinant genes into nondividing cells in vivo. First generation recombinant adenoviruses, rendered defective by deletion of sequences spanning E1a and E1b, express low levels of early and late viral genes that activate destructive cellular immune responses. Current strategies for improving recombinant adenoviruses attempt to inactivate other essential genes through deletion and growth in new packaging cell lines or incorporation of temperature sensitive mutations which allow propagation of the virus in available packaging cell lines at permissive temperatures. We describe in this report a new type of recombinant adenovirus that is deleted of all viral open reading frames. This recombinant (called delta-rAd), which contains only the essential cis elements (i.e., ITRs and contiguous packaging sequence), is propagated in 293 cells in the presence of E1-deleted helper virus. Concatamers of the monomeric vector genome were passaged and capable of transduction. The delta-rAd genome is packaged into virions that sediment at a lower density than the helper virus in cesium gradients forming the basis for a purification protocol. A fully deleted recombinant adenovirus that expresses human cystic fibrosis transmembrane conductance regulator was produced and used to transduce human airway epithelial cells derived from a cystic fibrosis patient. Packaging and propagation of a fully deleted adenovirus is an important step toward the development of a safer vector. Improved production and purification strategies need to be developed before this new vector system can be evaluated in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system
Luo, J., Deng, Z.-L., Luo, X., Tang, N., Song, W.-X., Chen, J., Sharff, K. A., Luu, H. H., Haydon, R. C., Kinzler, K. W., et al. (2007) · Nature Protocols · doi:10.1038/nprot.2007.135 · Cited by 854
Construction of adenovirus vectors through Cre-lox recombination
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., & Phipps, M. L. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1842-1849.1997 · Cited by 789
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., & Mehtali, M. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4805-4810.1996 · Cited by 653
Schiedner, G., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L., & Kochanek, S. (1998) · Nature Genetics · doi:10.1038/ng0298-180 · Cited by 648
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 635
Agah, R., Frenkel, P. A., French, B. A., Michael, L. H., Overbeek, P. A., & Schneider, M. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119509 · Cited by 606
Viral Vectors for Gene Therapy
Robbins, P. D., & Ghivizzani, S. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00020-5 · Cited by 529
Viral Vectors for Gene Transfer: A Review of Their Use in the Treatment of Human Diseases
Walther, W., & Stein, U. (2000) · Drugs · doi:10.2165/00003495-200060020-00002 · Cited by 442
Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12816 · Cited by 409
Morsy, M. A., Gu, M., Motzel, S., Zhao, J., Lin, J., Su, Q., Allen, H., Franlin, L., Parks, R. J., Graham, F. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7866 · Cited by 365
Persistence in muscle of an adenoviral vector that lacks all viral genes
Chen, H.-H., Mack, L. M., Kelly, R., Ontell, M., Kochanek, S., & Clemens, P. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1645 · Cited by 291
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors
Gregory, S. M., Nazir, S. A., & Metcalf, J. P. (2011) · Future Virology · doi:10.2217/fvl.11.6 · Cited by 89
“Since a helper virus is required for replication, contamination of the HD-AdV vector preparations with helper virus can occur [205], and the contamination can be hazardous.”
BackgroundAdenovirus vectors deleted for genes essential for viral DNA replication
Schaack, J. (2005) · Frontiers in Bioscience · doi:10.2741/1607 · Cited by 26
Metadata
- Authors
- FISHER, K. J., CHOI, H., BURDA, J., CHEN, S.-J., & WILSON, J. M.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 1996-03
- Volume
- 217
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W2081825650
- Cited by
- 291
- References
- 0
- FWCI
- 21.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.